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The liver is well known as that organ which is obligately required for the intrahepatocyte
development of the pre-erythrocytic stages of the malaria-causative agent Plasmodium.
However, largely neglected is the fact that the liver is also a central player of the host
defense against the morbidity- and mortality-causing blood stages of the malaria parasites.
Indeed, the liver is equipped with a unique immune system that acts locally, however,
with systemic impact. Its main “antipodal” functions are to recognize and to generate
effective immunoreactivity against pathogens on the one hand, and to generate tolerance
to avoid immunoreactivity with “self” and harmless substances as dietary compounds on
the other hand. This review provides an introductory survey of the liver-inherent immune
system: its pathogen recognition receptors including Toll-like receptors (TLRs) and its
major cell constituents with their different facilities to fight and eliminate pathogens.
Then, evidence is presented that the liver is also an essential organ to overcome
blood-stage malaria. Finally, we discuss effector responses of the liver-inherent immune
system directed against blood-stage malaria: activation of TLRs, acute phase response,
phagocytic activity, cytokine-mediated pro- and anti-inflammatory responses, generation
of “protective” autoimmunity by extrathymic T cells and B-1 cells, and T cell-mediated
repair of liver injuries mainly produced by malaria-induced overreactions of the liver-inherent
immune system.
Keywords: liver, hepatic immune system, tolerance, innate immunity, blood-stage malaria, Plasmodium,
erythrocytes, “protective” autoimmunity
LIVER-INHERENT IMMUNE SYSTEM
The liver is well known for its pivotal role in detoxification of
drugs, toxins, and other harmful substances, in protein, lipid,
carbohydrate, and vitamin metabolism, in steroidogenesis and
bile secretion as well as for its supporting functions of other
organs. Less known is the fact that the liver also plays a key
immunoregulatory role (Selmi et al., 2007; Crispe, 2009; Nemeth
et al., 2009; Parker and Picut, 2012). Indeed, the fetal liver is
the primary hematopoietic organ of mammals, and, postnatally,
the liver has retained the capability to exert important func-
tions of both innate and adaptive immunity (Parker and Picut,
2012).
The liver-inherent immune system acts locally in the liver,
but with systemic implications. Its two major functions are:
(i) to sense pathogens, as, e.g., RNA- and DNA-viruses, bac-
teria, fungi, parasitic protozoans, and to activate efficacious
inflammatory and immune responses against these pathogens;
(ii) to recognize concomitantly non-pathogenic antigens as
in harmless food compounds and to activate delicate mech-
anisms of immune hyporesponsiveness to generate tolerance
(Selmi et al., 2007; Crispe, 2009; Nemeth et al., 2009; Parker
and Picut, 2012). Both “antipodal” functions benefit from the
dual blood supply of the liver (Nemeth et al., 2009). The
hepatic artery delivers approximately 20% oxygenated blood
from the circulation, while the portal vein provides approxi-
mately 80% venous blood from the gastrointestinal tract. The
total blood of the human body is estimated to pass the liver
approximately 25 times per hour. During liver passage, the
blood percolates through a honeycomb of sinusoids with an
approximate diameter of 5–7 µm, by which the velocity of the
blood flow is slowed down to 25–250 µm/min (Nemeth et al.,
2009). This facilitates the liver cells to recognize blood-delivered
pathogens.
Pathogen recognition receptors (PRRs) represent a funda-
mental part of the liver-inherent immune system, that sense
the evolutionary highly conserved pathogen-associated molecular
patterns (PAMPs; Broering et al., 2011; Savva and Roger, 2013;
Kesar and Odin, 2014). There exists a large reservoir of hepatic
PRRs encompassing scavenger receptors (SRs) recognizing their
targets by specific glycosylation patterns, modified protein motifs,
and lipid moieties (Sorensen et al., 2012), cytoplasmic nucleotide-
binding oligomerization domain (NOD)-like receptors recogniz-
ing bacterial peptidoglycans, the retinoic acid inducible protein-I
(RIG-I) recognizing structural features of viral ssRNA, and, in
particular, Toll-like receptors (TLRs; Thompson and Locarnini,
2007). The binding of TLRs by their respective ligands activates
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innate and ensuing adaptive immune responses. There have been
identified 10 functional human TLRs and 12 functional mouse
TLRs, with TLRs 1–9 conserved in both humans and mice (Kawai
and Akira, 2010).
Toll-like receptors are expressed by the majority of liver cells,
though to varying levels (Chen and Sun, 2011). The TLRs 1, 2, 4,
5, and 6 are expressed on cell surfaces, whereas the TLRs 3, 7, 8,
and 9 are intracellularly localized in endolysosomal membranes
(Kawai and Akira, 2006). The TLRs, except TLR3, signal via
the adaptor protein myeloid differentiation factor-88 (MyD88)
ultimately activating nuclear factor kappa B (NFκB)-initiated and
other pathways.
Effectful responses of the liver-inherent immune system
against pathogens are generated by the orchestrated interplay of
differently specialized liver-resident cell populations whose main
“immune” functions are shortly outlined in the following.
Liver sinusoid endothelial cells (LSECs) form the fenes-
trated sinusoids-lining endothelium, which separates the sinusoid
lumen, without any basement membrane, from the underlying
space of Disse and the parenchyma tissue. LSECs represent about
45% of the non-parenchymal cells of the liver (Selmi et al., 2007;
Jenne and Kubes, 2013). They express the SRs-A, SR-B, and SR-C
as well as different TLRs. In response to ligands for TLRs 1, 2, 4, 6,
and 9, LSECs produce tumor necrosis factor α (TNFα), and TLR3
ligands induce interferon-γ (IFNγ), TNFα, and interleukin (IL)-6
(Wu et al., 2010). Moreover, LSECs express major histocompat-
ibility complex (MHC) class I and II molecules, co-stimulatory
molecules CD40, CD80, and CD86 and adhesion molecules, as,
e.g., intercellular adhesion molecule (ICAM) required for inter-
action with lymphocytes. Currently, LSECs are envisioned as to
represent an intricate platform for antigen presentation (Selmi
et al., 2007; Jenne and Kubes, 2013; Nakamoto and Kanai, 2014).
Hepatocytes (HCs) of the liver parenchyma encompass about
70–80% of all liver cells (Nemeth et al., 2009; Jenne and Kubes,
2013). HCs can express TLRs 1–9, though only TLR2 and TLR4
have been reported to be ligand-responsive to date (Liu et al.,
2002). HCs induce different innate immune responses (Nemeth
et al., 2009; Jenne and Kubes, 2013), but are also able to initi-
ate adaptive immune mechanisms. Indeed, HCs express MHC I
molecules, and inflammatory conditions even induce expression
of MHC II antigens (Franco et al., 1988), enabling HCs to present
antigen to naive T cells (Selmi et al., 2007; Nemeth et al., 2009;
Jenne and Kubes, 2013).
Different soluble components produced by HCs majorly con-
tribute to the acute phase response (APR), the first line of innate
systemic defense against pathogens. Acute inflammation induces
HCs to transiently increase their production of “positive” acute
phase proteins (APPs), whereas that of other “negative” APPs are
decreased (Steel and Whitehead, 1994; Parker and Picut, 2012).
The major positive APPs include serum amyloid A (SAA) and
C-reactive protein (CRP) in humans as well as SAA and the
CRP-homolog serum amyloid P (SAP) in mice, whose serum
concentrations during an APR can increase up to 1000-fold over
normal levels (Steel and Whitehead, 1994). Apart of these major
APPs, there are numerous other proteins produced in the liver
during infection, as, e.g., lipopolysaccharide binding protein,
haptoglobin, α2-macroglobulin, different proteinase inhibitors,
α1-antitrypsin, and α1-antichymotrypsin (Steel and Whitehead,
1994). Among the negative APPs are the plasminogen activator
inhibitor-1 (PAI-1) and the liver isoform of alkaline phosphatase
(AP; Steel and Whitehead, 1994). The latter has been used
classically as a serum biomarker for hepatic disease states such
as hepatitis, steatosis, cirrhosis, drug-induced liver injury, and
hepatocellular carcinoma (Pike et al., 2013).
Other soluble substances produced by HCs are complement
components, e.g., C3, that opsonizes pathogens for elimination,
and C9, that forms the membrane attack complex for final
microbe lysis (Parker and Picut, 2012). Moreover, HCs pro-
duce a number of circulating growth factors and inflammatory
cytokines, amongst which is also IL-6, that in turn induces
massive production of APPs by HCs (Parker and Picut, 2012).
This pleiotropic cytokine exerts both pro- and anti-inflammatory
properties and takes actions through two different signaling
mechanisms (Heinrich et al., 2003; Drucker et al., 2010; Scheller
et al., 2011). IL-6 “classic signaling” is restricted only to HCs
and immune cells, which are activated through their specificity-
defining membrane IL-6 receptor α (IL-6Rα) and the recruit-
ment of two chains of the signal-transducing membrane receptor
GP130, thus activating the Janus kinase/signal transducers and
activators of transcription (JAK/STAT) pathway. However, IL-
6 can also communicate with all other cells in the body by a
process termed “IL-6 trans-signaling.” Hereby, IL-6 binds to the
naturally occurring soluble IL-6Rα, which is derived by shedding
of the ectodomain of membrane IL-6Rα and by alternative mRNA
splicing in humans, but not mice. The IL-6/IL-6Rα complex can
bind to GP130 expressed ubiquituously in surface membranes of
all cells. However, the IL-6/sIL-6Rα complex can be inactivated
by binding soluble GP130 (sGP130), thus blocking IL-6 trans-
signaling (Knupfer and Preiss, 2008).
Kupffer cells (KCs) are located in the sinusoid lumen, adhere
to LSECs and represent about 30% of the non-parenchymal liver
cells (Parker and Picut, 2012). These liver-resident macrophages
constitute about 80–90% of the whole reticuloendothelial system
in the human body (Bilzer et al., 2006). The KCs presumably
derive from both local hematopoiesis in the liver as well as from
bone marrow-derived monocytes that enter the liver and even-
tually differentiate to liver-resident macrophages (Nemeth et al.,
2009; Jenne and Kubes, 2013). KCs are very versatile with a life-
span reaching from 1 week until 1 year. They express different sur-
face receptors allowing the detection, binding, and phagoyctosis
of pathogens. For instance, KCs express ligand-responsive TLRs
2–4 and TLR9 (Nakamoto and Kanai, 2014), SRs, the complement
receptors (CR)1 and CR3 as well as Fc receptors. Even if KCs are
not able to internalize and destroy pathogens, they have captured
on their surface as, e.g., Listeria monocytogenes, they recruit neu-
trophils from the circulation, which then take over destruction
of these pathogens (Gregory et al., 1996). Moreover, KCs are
involved in waste disposal, which also includes phagocytosis of
activated and apoptotic “self ” cells, as, for example, neutrophils,
platelets, and T cells. Upon stimulation, KCs produce a series of
cytokines among which are TNFα, IL-1β, IL-6, IL-12, and IL-18
(Kopydlowski et al., 1999). Moreover, KCs are capable of antigen
presentation. They express MHC I, MHC II and co-stimulatory
molecules required for activation of T cells. In particular, KCs
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can activate natural killer T (NKT) cells patrolling the sinusoids
(Jenne and Kubes, 2013).
Hepatic stellate cells (HSCs) or Ito cells reside in the space
of Disse, represent about 5–8% of total liver cells, and their
dendritic-like protrusions wrap around the sinusoids (Jenne and
Kubes, 2013). Apart from vitamin A storing and fibrinogenetic
cells, HSCs are able to present lipid antigens to NKT cells, enhance
proliferation of NKT cells and may present antigen to CD8+
T cells (Nemeth et al., 2009; Jenne and Kubes, 2013). Upon
activation, human HSCs express TLR4, along with CD14, and
the mouse HSCs TLRs 2 and 4 express vascular cell adhesion
molecule 1 (VCAM-1), transforming growth factor β1 (TGF-β1)
and monocyte chemoattractant protein-1 (MCP-1; Selmi et al.,
2007; Jenne and Kubes, 2013).
Dendritic cells (DCs) are concentrated around the portal
triad and around the central veins of the liver. There exist at
least five DC-types of with different “immature” phenotypes:
lymphoid DCs (CD8a+ B220− CD11b+), myeloid DCs (CD8−
B220− CD11b+), plasmacytoid DCs (CD8a− B220+), mixed lym-
phoid/myeloid DCs (B220− CD11b−), and natural killer (NK)
DCs (B220− CD11cint CD69+ 2B4+ DX5+; Selmi et al., 2007;
Nemeth et al., 2009; Jenne and Kubes, 2013). Hepatic DCs differ
from their counterparts in any classical lymphoid organ not only
by their immature phenotype, but also by less immunogenicity,
higher productions of cytokines, and higher endocytotic activity
(Hsu et al., 2007). They produce TNFα and IL-6 in response to
diverse ligand-activated TLRs. The ability of DCs to activate T
cells can be impaired by LSECs, which may be important for
induction and maintenance of immune tolerance. The major
function ascribed to hepatic DCs is to control the balance between
oral and portal autoimmune diseases (Selmi et al., 2007; Nemeth
et al., 2009).
Liver-resident lymphocytes, i.e., NK cells, NKT cells, T cells,
and B cells, account for about 25% of the non-parenchymal cells
of the liver. They differ from their corresponding cell populations
in other tissues in several aspects (Selmi et al., 2007; Crispe, 2009;
Jenne and Kubes, 2013).
Natural killer cells are large granular lymphocytes (LGLs),
represent about 35–50% of all liver-resident lymphocytes and
comprise a very heterogenous pattern (Nemeth et al., 2009). NK
cells in the liver are also more frequent than in any other tissues.
For instance, these innate lymphocytes are enriched more than
threefold in comparison to those in blood (Crispe, 2009). They
possess diverse PRRs which do not only recognize PAMPs, but
also damage-associated molecular patterns (DAMPs). NK cells
express ligand-responsive TLRs 1–4 and TLRs 6–9 (Sawaki et al.,
2007). Upon activation and in very close contact with target cells,
which may be opsonized by antibodies, NK cells release perforin
and various granzymes from their intracellular vesicle stores by
exocytosis, which kills foreign microbes (Lodoen and Lanier,
2006) and also malignant cells (Herbermann et al., 1975; Notas
et al., 2009). In addition, activated NK cells secrete numerous
cytokines, as, e.g., IFNγ, and are therefore considered as to shape
subsequent immune responses including modulation of MHC
expression by HCs and HSCs (Crispe, 2009).
Natural killer T cells are an abundant population amongst
liver-resident lymphocytes (Crispe, 2009; Nemeth et al., 2009;
Jenne and Kubes, 2013). Besides characteristic NK markers, NKT
cells also express a limited repertoire of T cell receptors (TCRs).
They are mainly CD4+, are restricted by CD1d molecules, and
display a LGL-morphology. There exist two populations, i.e.,
NK1.1+ TCRint (NKT cells) and NK1.1− TCRint (Abo et al.,
2012). Invariant NKT (iNKT) cells express the invariant TCRα
(Vα14-Jα18) in mice and Vα24-Jα18 in humans and respond to
various lipids in context with the non-classical MHC I molecule
CD1d (Bendelac et al., 2007). The CD1-dependent iNKT make
up to 30% of total hepatic lymphocytes, whereas their content in
blood is only 0.5%. Another group of NKT cells are the CD1d-
independent NK1.1+ T cells. Hepatic NKT cells are characterized
by peculiar features: (i) They apparently are the only cell popula-
tions among the liver-resident lymphocytes, which actively patrol
the hepatic vasculature for detecting pathogens. (ii) They can also
detect insults in further distant tissues and then act as modulators
of the global immune status. (iii) They might play a role in liver
autoimmune diseases upon tolerance breakdown (Nemeth et al.,
2009; Abo et al., 2012).
T cells contribute about 25% to the liver-resident lymphocytes
(Selmi et al., 2007; Crispe, 2009; Nemeth et al., 2009). Most
of them are extrathymic T cells developing outside the thymus
and express only intermediate amounts of TCR (Seki et al.,
1991; Abo et al., 2012). CD8+ T cells are more abundant than
CD4+ T cells in the liver (Selmi et al., 2007). Moreover, double
negative CD4− CD8− T cells occur in the liver and many of
them express γ ,δTCR instead of the conventional α,βTCR (Nemeth
et al., 2009). Most hepatic T cells have an activated phenotype;
for instance, CD25 and CD69 are expressed on CD8+ T cells.
The T cells in the liver differ in general from those in blood,
lymph nodes, and spleen by a lower ratio of CD4/CD8, higher
percentage of double positive CD3+ CD4+ CD8+ and double
negative CD3+ CD4− CD8−, as well as higher abundance of
γ ,δTCR cells. The latter represent about 15–25% of hepatic T
cells, but only 3% of blood T cells (Nemeth et al., 2009). T
cells can be activated through their TLRs 2, 3, and 9 (Gelmann
et al., 2004; Komai-Koma et al., 2004). Importantly, the liver
also contains several subsets of regulatory T (Treg) cells, and
specific Treg cells are assumed to play an important role in induc-
tion and maintenance of tolerance (Selmi et al., 2007; Crispe,
2009).
B cells represent less than 10% of the liver-resident lympho-
cytes in the human liver. In mice, the fetal and adult liver contains
B220low B-1 cells, being either CD5+ or CD5− (Tachikawa et al.,
2008; Baumgarth, 2011; Abo et al., 2012), with CD5 as a negative
regulator of B cell receptor signaling (Lankester et al., 1994).
Incidentally, B-1 cell development is negatively regulated by the
nuclear pregnane X receptor in the liver (Casey and Blumberg,
2012). The majority of intrahepatic B cells resembles conven-
tional B220high B-2 lymphocytes. B-2 cells are IgMlow IgDhigh
CD23+, while B-1 cells are IgMhigh IgDlow CD3− (Tachikawa
et al., 2008). B-1 and B-2 cells produce low affinity autoreactive
IgM antibodies, also termed natural antibodies (Baumgarth et al.,
2000). Most natural antibodies are polyreactive with numerous
“self ” and “non-self ” antigens and are involved in efficient control
of pathogens from circulation (Baumgarth et al., 2000), in the
clearance of senescent erythrocytes (Lutz et al., 1990), in removal
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of apoptotic bodies (Duan and Morel, 2006), and in autoimmune
diseases (Ochsenbein and Zinkernagel, 2000).
THE LIVER: EFFECTOR ORGAN AGAINST BLOOD-STAGE
MALARIA
The malaria-causative agents are parasitic protozoans of the
genus Plasmodium. These are transmitted by Anopheles and reach
via the bloodstream the liver, in which they invade HCs and
undergo asexual multiplication (Frevert and Nacer, 2013). This
pre-erythrocytic development of the parasites in the liver pro-
ceeds clinically asymptomatic, it is not preventable by the liver-
inherent immune system, though it may possibly benefit, at least
transiently, from the tolerogenic properties of the liver (Frevert,
2004). Then, merozoites are released from HCs, which penetrate
erythrocytes and the ensuing asexual multiplication in erythro-
cytes is associated with morbidity and mortality of malaria.
Blood-stage malaria afflicts about 225 million people and kills
about 781,000 people, mainly African children, worldwide per
annum (Garcia, 2010; WHO, 2010). The majority of the malaria-
afflicted people can obviously cope with the infections. Repeated
blood-stage infections in malaria endemic areas obviously lead,
though slowly, to acquisition of natural immunity against the
blood-stage malaria. This natural immunity is not solid: it reduces
disease symptoms, but it does not prevent re-infections with
elevated blood parasitemias during malaria season. It is specific
for species and strain of Plasmodium, and it is short-lived (Cohen
and Lambert, 1982). It appears as if the slow acquisition of natural
immunity may be associated with increasing tolerance generated
by the liver against malarial blood-stages, though experimental
evidence for this view is lacking.
The spleen is currently considered as to be the central effector
site of host immunity against blood-stage malaria (Chotivanich
et al., 2002; Engwerda et al., 2005; Del Portillo et al., 2012).
The spleen is equipped with mechanisms to eliminate senes-
cent and aberrant red blood cells (RBCs) including parasitized
RBCs (pRBCs). However, previous studies with the experimental
malaria P. yoelii have already revealed that mice, after vaccination
and splenectomy, are still able to clear blood-stage infections,
albeit at delayed recovery (Playfair et al., 1979; Dockrell et al.,
1980). Also, splenic uptake of injected labeled pRBCs during
infections with P. yoelii decreased with progressing course of
infection. Concomitantly, however, the liver has increased its
uptake of pRBCs.
Similarly, it has been found in P. chabaudi-infected mice that,
during the crisis phase of infection, which is characterized by
a dramatic decline of peripheral parasitemia from about 35–
55% at peak parasitemia to about 1–2% within 3–4 days, the
spleen, though dramatically enlarged, becomes “closed” for entry
of particulate material. Indeed, the spleen excludes uptake of
injected labeled pRBCs or inert polystyrol beads, but not that
of fluorescently labeled bovine serum albumin (Krücken et al.,
2005, 2009). Concomitantly, however, the liver has increased
its trapping capacity of particles (Krücken et al., 2005, 2009).
Moreover, the importance of the liver against blood-stage malaria
is particularly demonstrated in lymphotoxin β receptor (LTβR)-
deficient mice which have severe defects of the spleen and have
also lost all other secondary lymphoid organs (Fütterer et al.,
1998). Nevertheless, these LTβR-deficient mice are even more
resistant to blood-stage malaria of P. chabaudi than the corre-
sponding control mice (Wunderlich et al., 2005). These findings
support the view that the liver with its immanent immune system
is also a major—if not essential—player of the host defense against
blood-stage malaria, though this aspect has been largely neglected
by research to date.
LIVER EFFECTORS TOWARD BLOOD-STAGE MALARIA
Evidence is increasing that the liver-resident immune system
is obviously able to respond to blood-stage malaria with the
development of efficient anti-malaria effector mechanisms.
Toll-like receptors are activated in the liver by blood-stage
malaria. Indeed, experimental malaria with P. chabaudi induces
significant increases in mRNA expression of Tlr 1, 2, 4, 6, 7, and
8, varying between 4- and 21-fold in the liver of C57BL/6 mice
(Al-Quraishy et al., 2014). By contrast, the expression of Tlr3,
Tlr5, and Tlr9 does not respond to malaria infection at all. It is
conspicuous that the mRNA levels of both the surface-localized
TLR1, TLR2, and TLR6, as well as the intracellular TLR7 and
TLR8 are increased.
TLR1 and TLR6 are currently regarded as auxiliary recep-
tors, which both form heterodimers with TLR2 in the plasma
membrane (Kawai and Akira, 2010; Oliveira-Nascimento et al.,
2012). These heterodimers of both TLR2/1 and TLR2/6 recognize
a broad spectrum of different PAMPs, in particular multiple diacyl
lipopeptides of various infectious agents such as viruses, bacteria,
fungi, and parasites (Oliveira-Nascimento et al., 2012; De Almeda
et al., 2013; Misch et al., 2013; Zhang et al., 2013). PAMPs recogni-
tion then activates a cascade of downstream reactions eventually
leading to innate and adaptive immune responses directed against
pathogens and, also, to protection from those adverse processes
induced by host responses to infections (Kawai and Akira, 2010;
Oliveira-Nascimento et al., 2012). In human malaria with P.
falciparum, the TLR2/1 and TLR2/6 complexes recognize specific
components of the glycosylphosphatidylinositols (GPIs), that are
regarded as major factors contributing to malaria pathogenesis
(Krishnegowda et al., 2005). Thus, TLR2/1 recognizes intact 3-
acyl-GPIs and TLR2/6 the sn-2-lyso-GPI components (Krishne-
gowda et al., 2005). Remarkably, expression of Tlr6 and Tlr1, but
not that of Tlr2, Tlr7, and Tlr8, are under epigenetic control, since
blood-stage infections of P. chabaudi induce alterations of the
DNA methylation status of the promoters of Tlr1 and Tlr6 genes
(Al-Quraishy et al., 2013). This malaria-induced epigenetic fine-
tuning of Tlr6 and Tlr1 in the liver may be an important initial
step of the host response against Plasmodium blood stages. Since
DNA methylation is stable (Bird, 2002), it may be further sus-
pected that epigenetic fine tuning of Tlr6 and Tlr1 may contribute
to memory against homolog re-infections.
In contrast to Tlr1 and Tlr6, the DNA methylation status of
the Tlr8 gene promoter is not affected by P. chabaudi infections at
all. The function of TLR8, intracellularly localized in endosomal
membranes, are not yet well understood (Cervantes et al., 2012;
Kesar and Odin, 2014). TLR8 has been shown to sense single-
stranded RNA of viral origin and bacterial RNA as well as to
induce NFκB-dependent cytokines and type I IFNs. However,
increasing information suggests that TLR8, possibly in cross-talk
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with TLR7 (Wang et al., 2006), is involved in the generation of
autoimmunity (Krieg and Vollmer, 2007; DeMaria et al., 2010).
Remarkably, dysregulations of Tlr8 and Tlr6 occur, when P.
chabaudi infections are induced by testosterone to take a lethal
outcome in female mice (Al-Quraishy et al., 2014).
ACUTE PHASE RESPONSE
An APR is experimentally inducible by blood-stage malaria,
without any preceding pre-erythrocytic development of parasites
in the liver, in humans and model systems. When in human
volunteers an APR is induced by injecting P. falciparum-infected
RBCs, serum levels of α1-acid glycoprotein (AGP) peak within
1 week (Klainer et al., 1968). AGP inhibits in vitro growth of
P. falciparum by more than 80% at a concentration of 2.5–
3.0 mg/ml, which resembles those levels reached during a typical
APR in humans (Friedman, 1983). Other APPs such as α1-
antitrypsin, transferrin or α2-macroglobulin have been reported
to be not as effective against P. falciparum in vitro (Friedman,
1983). Patients suffering from malaria reveal elevated serum CRP
which binds to the patients’ RBCs. These in turn loose their nor-
mal discoid-shape, increase membrane fluidity and hydrophobic-
ity and decrease their effective complement-regulatory proteins
(Ansar et al., 2009). In mice, blood-stage infections of both self-
healing P. chabaudi and P. vinckei as well as lethal P. berghei induce
an APR characterized by increased serum levels of the major APP
SAP (Balmer et al., 2000). In accordance, the mRNA levels of Saa
1–3 in the liver increased by 65- to 80-fold at peak parasitemia
of P. chabaudi infections (Krücken et al., 2005). By contrast,
a reduced APR in association with a significant extension of
primary parasitemia is induced in IL-6-deficient mice in response
to blood-stage infections. This suggests that the APR induced
by blood-stage infections contributes to an antiparasitic and/or
immunomodulatory immune response (Balmer et al., 2000).
It is remarkable, however, that negative APPs, as, e.g., hap-
toglobin, PAI-1, and AP with potentially efficient anti-malaria
activity, are decreased during the APR against blood-stage
malaria. For instance, haptoglobin is malaria-protective, since it
is toxic to P. falciparum-infected RBCs. Its main function is to
bind hemoglobin released from erythrocytes and to support its
elimination, thereby also preventing oxidative stress in the blood
(Imrie et al., 2004). Hypohaptoglobinemia has been introduced
as a biochemical and epidemiological marker of P. falciparum
malaria (Mohapatra et al., 1999). In experimental P. chabaudi
malaria, the Pai-1 gene is downregulated in the liver. Since Pai-
1-deficient mice cannot control parasitemia as good as wild type
mice, PAI-1 has been suggested to be required for parasitemia
control (Krücken et al., 2005). AP is also reduced at peak par-
asitemia during self-healing P. chabaudi infections (Wunderlich
et al., 2005). AP exerts anti-inflammatory effects, as it is capable
of dephosphorylating potentially deleterious molecules and of
reducing inflammation and coagulopathy systemically (Pike et al.,
2013). Obviously, the blood stages of the malaria parasites benefit
from the down-regulation of negative APPs during an APR.
INFLAMMATORY RESPONSE
Course and outcome of both human and experimental blood-
stage malaria critically depend on a finely tuned balance between
both pro-inflammatory cytokines, as, e.g., IL-1β, TNFα, IFNγ, IL-
6, and IL-12, and anti-inflammatory cytokines such as IL-4 and
IL-10 (Bakir et al., 2011; Perkins et al., 2011).
In different experimental models, the liver has been shown
to produce different cytokines in response to primary blood-
stage malaria. However, there are differences between lethal and
self-healing infections. In lethal P. chabaudi malaria, there occurs
biphasic, two-wavy increase in serum IL-1β, TNFα, and IL-6 with
the first wave peaking on day 1 p.i. and the second wave peaking
at maximal parasitemia on day 8 p.i. (Wunderlich et al., 2012). In
parallel, the liver biphasically produces mRNAs coding for IL-1β,
TNFα, and IL-6 (Krücken et al., 2009). By contrast, the hepatic
production of IFNγ mRNA reveals a lower and more uniform
increase during precrisis. This pattern of mRNA production is
totally reverted after protective vaccination of mice. Then, the
liver produces a pronounced biphasic increase of IFNγ mRNA
at higher levels, while the mRNA levels of IL-1β, TNFα, and
IL-6 are lower and the biphasic production pattern has largely
disappeared (Krücken et al., 2009). This indicates that protection
against blood-stage malaria is associated with low production of
IL-1β, TNFα, IL-6 and a high biphasic production IFNγ by the
liver. Incidentally, a two-wavy production pattern, as well as its
disappearance after protective vaccination, can be also found for
the mRNA production of inducible nitric oxide synthase (iNOS),
arginase, and different nuclear receptors including pregnane X
receptor in the liver (Krücken et al., 2009).
In mice infected with a non-lethal strain of P. yoelii, the
liver has been also shown to produce mRNAs of both pro-
inflammatory cytokines, i.e., IFNγ, IL-12 p40, IL-6, and TNFα,
and anti-inflammatory cytokines such as IL-4 and IL-10 (Bakir
et al., 2011). Both pro- and anti-inflammatory cytokines are
highly expressed during precrisis of blood-stage infections. It
has been suggested that the pro-inflammatory cytokines induce
the immune system to take action, while the anti-inflammatory
cytokines counteract the high levels of inflammatory cytokines
(Bakir et al., 2011).
The liver-produced cytokines are not only important for the
local response in the liver, but also have presumably an impact
for the systemic response to blood-stage malaria. For instance,
a rather complex and dynamic interplay has been evidenced for
IL-6. This pleiotropic cytokine is produced not only by HCs,
but also by KCs and other liver cells. The severity of blood-stage
malaria correlates with circulating IL-6 levels. Increased levels
have been described in patients suffering from malaria caused
by P. falciparum and P. vivax (Kern et al., 1989; Jason et al.,
2001; Lyke et al., 2004; Robinson et al., 2009), often associated
with polyclonal B cell activation (Donati et al., 2004). Conversely,
decreasing IL-6 levels are reported to be associated with decreas-
ing parasitemia (Sarthou et al., 1997) and hyperpyrexia (Seoh
et al., 2003), as well as after anti-malarial treatment (Hugosson
et al., 2006). In experimental murine malaria, it has been shown
that IL-6 trans-signaling, rather than classic IL-6 signaling, con-
tributes to malaria-induced lethality (Wunderlich et al., 2012).
Indeed, approximately 50% of IL-6Rα-deficient mice survive an
otherwise lethal P. chabaudi blood-stage malaria. However, the
lethal outcome is restored, when IL-6 trans-signaling is induced
by injecting mouse recombinant sIL-6Ra in the IL-6Rα-deficient
www.frontiersin.org November 2014 | Volume 5 | Article 559 | 5
Wunderlich et al. Liver in blood-stage malaria
mice. By contrast, inhibition of IL-6 trans-signaling through
injecting recombinant sGP130Fc protein in wild type mice results
in 40% survival (Wunderlich et al., 2012).
PHAGOCYTIC ACTIVITY
Intraerythrocytic stages of Plasmodium produce and store hemo-
zoin in their phagosomes to detoxify the lytic ferriprotoporphyrin
IX released during digestion of host hemoglobin by parasites
(Olivier et al., 2014). Since ferriprotoporphyrin IX is also lytic
for host cells including human RBCs (Orjih et al., 1988), the
hemozoin is therefore cleared from the circulation as potentially
dangerous waste material by phagocytosis of KCs to protect host
cells.
On the other hand, KCs are also known to be endowed with
the capacity to phagocytose and to remove senescent and aberrant
erythrocytes including pRBCs from circulation (Otogawa et al.,
2007; Lee et al., 2011) mediated by specific SRs (Terpstra and van
Berkel, 2000). It has been therefore suspected that at least part
of the intracellularly accumulated hemozoin in KCs is derived
from internalized and decayed pRBCs. This view is supported
by several findings. In rats with a high load of P. berghei blood-
stage infections, KCs exhibit a markedly increased phagocytic
activity, presumably due to an upregulation of scavenger activity
for erythrophagocytosis (Nobes et al., 2002). Moreover, it has
been shown in P. berghei-infected rats that the number of KCs
is significantly increased and the phagocytic activity of KCs on
a cell-by-cell basis is enhanced (Murthi et al., 2006). Further-
more, at peak parasitemia of P. chabaudi-infected mice, KCs are
characterized by hyperplasia, and the massively enlarged KCs take
on a “foamy” appearance detectable by light microscopy (Delic
et al., 2010). These KCs contain, besides hemozoin, also regularly
pRBCs inside the area of sectioned KCs thus supporting the view
that KCs are indeed able to erythrophagocytose pRBCs and to
destroy them in their phagosomes in vivo.
Several studies in non-KC macrophages have shown that inges-
tion of hemozoin by macrophages severely impairs macrophage
activities upon diverse stimulations. For instance, hemozoin dra-
matically reduces the production of IL-6, but increases pro-
duction of TNFα (Prada et al., 1995) and inhibits activities of
NADPH-oxidase activity (Schwarzer and Arese, 1996) and protein
kinase C (Schwarzer et al., 1993). Moreover, the production of
reactive oxygen species (ROS) and reactive nitrogen species (RNS)
is inhibited (Schwarzer et al., 1993; Prada et al., 1996) and the
expression of MHC II molecules, CD54 and CD11c is impaired
(Schwarzer et al., 1998). However, hemozoin does not specifically
affect expression of MHC I molecules, CD16 (low affinity Fc
receptor for aggregated IgG), CD64 (high affinity receptor for
IgG), CD11b (receptor for complement receptor iC3b), CD35
(receptor for complement components C3b and C4b), and CD36
(non-class-A SR; Schwarzer et al., 1998; Olivier et al., 2014). More
recent data indicate that hemozoin can induce the production of
IL-1β through the NOD-like containing pyrin 3 domain (NLRP3)
inflammasome complex (Olivier et al., 2014). These data suggest
that also in vivo activities of KCs may be negatively affected by
ingested hemozoin. Indirect evidence for this view is provided by
a magnetometric and electron microscopal study showing that
ingestion and metabolism of P. chabaudi-infected RBCs by KCs
in vivo decrease intracellular organelle motion in these KCs, which
probably compromises host defense reactions (Bellows et al.,
2011).
“PROTECTIVE” AUTOIMMUNITY
In humans, acquisition of natural immunity against blood-
stage malaria is associated with the emergence of autoimmunity
(Butcher, 2008). A number of studies with murine blood-stage
malaria have substantiated the view that autoimmunity arises
during blood-stage malaria and that the liver-inherent immune
system is critically involved in the generation of this “anti-
malaria” autoimmunity. This is presumably not mediated by
conventional T and B cells, but rather by special populations of
hepatic T and B cells of innate immunity (Abo et al., 2012). For
instance, P. yoelii infections have been reported to induce severe
thymic atrophy in mice, which ultimately arrests production of
conventional T cells (Abo et al., 2012). Concomitantly, however,
extrathymic IL-2Rb+ CD3int T cells and its subset NK1.1− CD3int
expand in the liver. Moreover, NK1.1− TCRint cells are present in
the liver of athymic nude mice, which harbor neither conventional
T cells nor NKT cells of thymic origin. When lymphocytes are iso-
lated from the liver of athymic mice recovered from blood-stage
malaria of non-lethal P. yoelii, these “immune” lymphocytes can
confer protection from malaria to both irradiated euthymic and
athymic mice (Mannoor et al., 2002). Furthermore, autoreactive
extrathymic T cells have been described in the liver of malaria-
infected mice, which react with both HCs and RBCs of malaria-
infected mice (Abo et al., 2012).
In parallel with the expansion of extrathymic autoreactive T
cells, the number of B220low B-1 cells is also increased in the liver
and is highest around peak parasitemia in mice infected with non-
lethal P. yoelii (Kanda et al., 2010; Abo et al., 2012). These B-1 cells
produce autoantibodies against nucleus, ss- and dsDNA (Kanda
et al., 2014). In accordance, serum levels of both IgM- and IgG-
type autoantibodies against denatured DNA increased during
non-lethal P. yoelii infections in mice, both peaking around peak
parasitemia (Bakir et al., 2011). These immune responses resem-
ble those found in autoimmune diseases (Bakir et al., 2011). In
vivo depletion of autoreactive B-1 cells and subsequent infection
with normally self-healing P. yoelii result in death of 56% of mice
(Mannoor et al., 2013). By contrast, adoptive transfer of such
auto-antibody secreting B cells prior to infecting with P. yoelii
leads to later appearance and inhibition of parasitemia (Mannoor
et al., 2013). Auto-antibodies secreting B220low B-1 cells have been
suggested to target “abnormal self ” cells, as, e.g., HCs and RBCs,
in malaria-infected mice, and such autoantibody-labeled cells can
be further processed and eliminated by macrophages and KCs
(Kanda et al., 2014).
Previous authors have already suggested that autoimmunity
plays a key regulatory role in protection from malaria (Jayawar-
dena et al., 1979; Jarra, 1980). In accordance, it has been recently
found that autoantibodies and sera from patients suffering from
diverse autoimmune conditions, but not from malaria, inhibit
the in vitro growth of P. falciparum in human RBCs (Bhatnagar
et al., 2011; Brahimi et al., 2011). Especially that type of autoim-
munity is apparently required for protection against blood-
stage malaria (Daniel-Ribeiro, 2000), that is presumably directed
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against autoantigens and parasite-induced neo-autoantigens on
the surface of Plasmodium-infected RBCs (Wunderlich et al.,
1988b,c; Fontaine et al., 2012). It is therefore not surprising that
surface membranes of Plasmodium-infected RBCs can be used for
protective vaccination of malaria-susceptible mice, which raises
their survival from 0 to more than 80% and decreases peak
parasitemia by about 30% (Wunderlich et al., 1988a; Krücken
et al., 2009).
Collectively, the currently available information supports the
view that the generation of autoimmunity and/or the enhance-
ment of already existing low level “natural” autoimmunity in the
liver may be an integrative—if not the essential—part of pro-
tective immunity against blood-stage malaria (Abo et al., 2012).
Malaria-activated TLR8, possibly in cross-talk with TLR7, has
been speculated to be involved in the generation and/or surveil-
lance of this “protective” autoimmunity (Al-Quraishy et al.,
2014).
LIVER INJURIES AND REPAIR
Blood-stage malaria causes severe injuries of the liver. Humans
infected with P. falciparum or P. vivax have been described to
suffer from hepatic dysfunctions and malarial hepatitis with jaun-
dice and raised liver enzyme levels in the blood (Ananad et al.,
1992; Kochar et al., 2003; Nautiyal et al., 2005). Liver injuries
have been also found postmortem in fatal human malaria, as,
e.g., KC hyperplasia, hemozoin accumulation within KCs, liver-
necrosis, portal inflammation, steatosis, and cholestasis (Rupani
and Amarapurkar, 2009). Similar histopathological injuries have
been also observed in the liver of mice primarily infected with
lethal P. chabaudi at peak parasitemia, besides increased serum
levels of hepatic markers such as aspartate aminotransferase
(AST), alanine aminotransferase (ALT), bile acids, and bilirubin
(Krücken et al., 2005; Delic et al., 2010). However, similar changes,
though not as pronounced, also occur in the liver of mice when
P. chabaudi infections take a self-healing course (Krücken et al.,
2005; Delic et al., 2010).
Liver injuries are presumably not directly induced by the
parasites, but largely indirectly as infection-induced overreactions
of the liver-inherent immune system, as, e.g., increased oxidative
stress induced by ROS/RNS produced during phagocytic activ-
ity of KCs, increased production of proinflammatory cytokines,
increased release of perforin, granzymes, and lysosomal enzymes
by LGL, autoreactive cytotoxic T cells, and “bystander killing” of
liver cells due to cell-mediated cytotoxicity. For instance, hepatic
CD1d-independent DX5+ T cells have been shown to cause
“bystander killing” in the liver of P. berghei-infected mice (Adachi
et al., 2004). Hepatotoxicity can be also induced by hepatic CD1d-
restricted NKT cells activated during blood-stage malaria through
IL-12 secreted from KCs (Gonzalez-Aseguinolaza et al., 2000).
Damages of liver cells have been suggested to be surveilled by
DAMPs-activated TLRs (Adachi et al., 2001).
Even an apparent “non-immune” mechanism generating liver
injury is very likely immune-mediated, as, for example, the almost
doubling of the ammonia content in the blood plasma found
at peak parasitemia during lethal P. chabaudi malaria (Delic
et al., 2010). The increased systemic ammonia level signalizes
severe local hepatic dysfunctions. Indeed, the liver metabolism is
impaired, in particular the detoxifying capacity of the liver, evi-
denced as massive down-regulations of genes encoding enzymes
involved in phase I–III metabolism (Krücken et al., 2005; Delic
et al., 2010). However, similar changes in liver metabolism can
be experimentally induced in mice only by injections of TNFα
and IL-1β without any malaria infection (Kim et al., 2004,
2007). Increases in systemic ammonia levels presumably also
cause dysfunctions of other organs. For instance, the brain is
particularly sensitive to ammonia intoxication, which ultimately
leads to hepatoencephalopathy (Butterworth, 2002; Häussinger
and Schliess, 2008), that has been indeed reported to occur as
a severe complication in P. falciparum-infected patients (Kochar
et al., 2003; Whitten et al., 2011).
However, the liver also possess the capability for fast regen-
eration of destructed liver tissue. This capability also involves T
cell-mediated repair mechanisms of the liver-inherent immune
system. For instance, P. chabaudi blood-stage infections in mice
have been described to induce an increase of liver-resident IL-
17- and IL-22-producing CD8+ T cells (Mastelic et al., 2012).
In contrast to IL-17 producing T cells, the IL-22 producing T
cells very likely protect from the potentially lethal effects of liver
damages during primary P. chabaudi infections. Further work is
required to disentangle those host mechanisms in the liver, which
mediate repair and healing of liver tissue injured during blood-
stage malaria, and those, which contribute to liver dysfunctions
and ultimately to multiple organ failure as the reason for malaria
mortality (Delic et al., 2010).
CONCLUDING REMARKS
The importance of the liver-inherent immune system as part
of the host defense against blood-stage malaria is increas-
ingly recognized, though still too hesitatingly. The liver-inherent
immune system is able to develop several different effector
responses against malarial blood stages. Development and effi-
cacy of these blood-stage effectors may be modulated by those
immune responses which are previously elicited against the pre-
erythrocytic liver stages of the malaria parasites (Klotz and Fre-
vert, 2008) and, conversely, the latter may be even boosted by
the blood-stage effectors (Ocana-Morgner et al., 2003; Lau et al.,
2014).
Overreactions of the effector responses directed against blood-
stage malaria presumably lead to severe inflammatory liver
injuries having systemic impact. Such overreactions are puzzling
since the liver-inherent immune system is also known for its
capability to generate tolerance, a state of immune hyporespon-
siveness. The “tolerogenic” milieu of the liver may be considered
to be beneficial for blood-stage parasites of different Plasmodium
species including P. falciparum and P. chabaudi to escape anti-
malaria effectors by intrahepatic sequestration (Medeiros et al.,
2013; Brugat et al., 2014). Though intrahepatic sequestration
mediated by CD36 has been reported to be fundamentally impor-
tant for parasite growth in vivo (Fonager et al., 2012), parasite
sequestration also occurs in other “non-tolerogenic” organs.
It is also puzzling how a tolerogenic hyporesponsive milieu
as in the liver allows the generation of specific autoimmunity at
all, that is presumably even an integrative—if not the essential—
part of protective immunity against blood-stage malaria. This
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autoimmunity is mediated by autoreactive extrathymic T cells and
autoantibody-producing B-1 cells. One target of autoimmunity is
the RBC, the host cell of the malaria blood stages. Remarkably,
surface membranes of Plasmodium-infected RBCs, but not those
of non-infected RBCs, can be used for protective vaccination
of mice (Wunderlich et al., 1988a; Krücken et al., 2009). This
raises survival of malaria-susceptible mice from 0 to more than
80%, decreases parasitemia and concomitantly attenuates overre-
actions of hepatic inflammation induced by blood-stage malaria
of P. chabaudi. This vaccination model appears rather convenient
to trace those immune and possible autoimmune mechanisms,
which have to be activated and/or suppressed in the liver to
generate efficient protection against blood-stage malaria. Such
knowledge in turn will advance our understanding of how these
mechanisms can be utilized for the design of an effective human
anti-malaria vaccine.
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